Category

Archives

Blog of Signaling Pathways

JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL

388 views | Nov 28 2022

Aissa Benyoucef et al. revealed the novel involvement of ZEB2/LSD1 complexes in repressing the intrinsic apoptosis pathway by inhibiting the expression of several pro-apoptotic proteins such as BIM (BCL2L11) as a major driver for ETP-ALL survival. [Read the Full Post]

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

361 views | Nov 27 2022

Naseema Gangat et al. suggested a short-term survival benefit associated with anemia response in momelotinib-treated patients with MF. [Read the Full Post]

MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis

375 views | Nov 27 2022

Vikas Gupta et al. suggested that MAIC-adjusted improvements observed in SVR35 and TSS50 at Week 24 with pelabresib and ruxolitinib vs. ruxolitinib, fedratinib, or momelotinib monotherapy were consistent with unadjusted comparisons. [Read the Full Post]

Inhibition of focal adhesion turnover prevents osteoblastic differentiation through β-catenin mediated transduction of pro-osteogenic substrate

225 views | Nov 26 2022

Otto J Juhl 4th et al. suggested that the observed β-catenin translocation is a result of focal adhesion turnover, providing evidence for a focal adhesion initiated, β-catenin mediated mechanism of substrate surface signal transduction. [Read the Full Post]

Theta dominates cross-frequency coupling in hippocampal-medial entorhinal circuit during awake-behavior in rats

195 views | Nov 26 2022

Yuchen Zhou et al. found that theta is the dominant frequency of cross-frequency coupling between the MEC and hippocampus, with hippocampal gamma largely independent of entorhinal gamma. [Read the Full Post]

Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors

85 views | Nov 25 2022

Letizia Granieri et al. thought that RRM2 was a USP7 target and was regulated by USP7 during S phase of the cell cycle. [Read the Full Post]

The multifaceted roles of USP7: new therapeutic opportunities

119 views | Nov 25 2022

Benjamin Nicholson et al. thought that USP7 inhibitors held promise as a new strategy for the treatment of disease. [Read the Full Post]

Visfatin Amplifies Cardiac Inflammation and Aggravates Cardiac Injury via the NF- κ B p65 Signaling Pathway in LPS-Treated Mice

75 views | Nov 24 2022

Yewen Hu et al. thought that visfatin might be a clinical target for preventing cardiac injury in sepsis. [Read the Full Post]

OXPHOS deficiency induces mitochondrial DNA synthesis through non-canonical AMPK-dependent mRNA compartmentalization

97 views | Nov 24 2022

Milon Banik et al. inferred that AMPK was locally activated by inhibition of the F1F0 ATP synthase to stimulate association of mtDNA replication factor mRNAs, leading to stimulation of mtDNA synthesis. [Read the Full Post]

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

87 views | Nov 23 2022

Xiaoying Qian et al. thought that first-line immunotherapy had promising therapeutic potential in the treatment of PSC. [Read the Full Post]

LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

194 views | Nov 23 2022

Donatella Delle Cave et al. identified a highly metastatic subpopulation of TICs marked by LAMC2. [Read the Full Post]

Hypoxia inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells

136 views | Nov 22 2022

Masanobu Tsubaki et al. indicated that HIF-1α regulated BCR-ABL and Met expression and was involved in cell survival in CML cells. [Read the Full Post]

Identification of biomarkers and key pathways in synovial sarcoma cells exposed to anlotinib by integrating bioinformatics analysis and experimental validation

171 views | Nov 22 2022

Xiaoli Liu et al. identified biomarkers and key pathways associated with the effects of anlotinib treatment in SS cells. [Read the Full Post]

Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial

326 views | Nov 21 2022

Samar A Dewidar et al. thought that concomitant use of pitavastatin with standard neoadjuvant chemotherapy protocols might improve neoadjuvant chemotherapy responses in patients with breast cancer. [Read the Full Post]

Role of the Glycogen Synthase Kinase 3-Cyclic AMP/Protein Kinase A in the Immobilization of Human Sperm by Tideglusib

173 views | Nov 21 2022

Weiwei Wang et al. found the GSK3-cAMP/PKA regulatory loop in human sperm, which might mediate the immobilization effect of tideglusib at low of concentrations (e.g., 1.25 μM) on sperm motility. [Read the Full Post]

Hepatic ER stress suppresses adipose browning through ATF4-CIRP-ANGPTL3 cascade

127 views | Nov 20 2022

Sihan Lv et al. identified a communication mechanism to link hepatic ER stress and adipose browning that might imply a reciprocal regulation of obesity and liver steatosis. [Read the Full Post]

Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study

103 views | Nov 20 2022

Hidenori Sakata et al. the safety profile in this EPPV study was similar to that from the phase III BEACON CRC study and no new safety concerns were identified. [Read the Full Post]

Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma

98 views | Nov 18 2022

Liangming Zhang et al. found that EXO1 facilitated PD-L1 and sPD-L1 expression in LUAD cells. [Read the Full Post]

Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations

117 views | Nov 18 2022

Galit Livnat et al. demonstrated the clinical efficacy of ETI in pwCF carrying CFTR processing non-F508del mutations which were predicted to respond by in vitro studies. [Read the Full Post]

PI3Kγ controls IL-17A expression and attenuates alveolar bone loss in an experimental periodontitis model

87 views | Nov 17 2022

Marcelo Franchin et al. thought that PI3Kγ played an important role in modulating IL-17A expression and alveolar bone loss in vivo. [Read the Full Post]